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Abstract
Background: Filarial nematodes are tissue-dwelling parasites that can be killed by Th2-driven immune effectors, but that
have evolved to withstand immune attack and establish chronic infections by suppressing host immunity. As a
consequence, the efficacy of a vaccine against filariasis may depend on its capacity to counter parasite-driven
immunomodulation.
Methodology and Principal Findings: We immunised mice with DNA plasmids expressing functionally-inactivated forms of
two immunomodulatory molecules expressed by the filarial parasite Litomosoides sigmodontis: the abundant larval
transcript-1 (LsALT) and cysteine protease inhibitor-2 (LsCPI). The mutant proteins enhanced antibody and cytokine
responses to live parasite challenge, and led to more leukocyte recruitment to the site of infection than their native forms.
The immune response was further enhanced when the antigens were targeted to dendritic cells using a single chain Fv-
aDEC205 antibody and co-administered with plasmids that enhance T helper 2 immunity (IL-4) and antigen-presenting cell
recruitment (Flt3L, MIP-1a). Mice immunised simultaneously against the mutated forms of LsALT and LsCPI eliminated adult
parasites faster and consistently reduced peripheral microfilaraemia. A multifactorial analysis of the immune response
revealed that protection was strongly correlated with the production of parasite-specific IgG1 and with the numbers of
leukocytes present at the site of infection.
Conclusions: We have developed a successful strategy for DNA vaccination against a nematode infection that specifically
targets parasite-driven immunosuppression while simultaneously enhancing Th2 immune responses and parasite antigen
presentation by dendritic cells.
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Introduction
DNA vaccination is a promising technology that is being
developed to combat diseases such as flu, HIV, and cancer [1].
Furthermore, the stability and relatively low production cost of
DNA vaccines provide hope for treating individuals in developing
countries. After more than 20 years of mass drug treatment
programs based on a limited choice of drugs, lymphatic filariasis
and onchocerciasis remain major public health problems. Control
programs in some areas are now threatened by the emergence of
drug-resistance [2,3], while in communities where both oncho-
cerciasis and loiasis are endemic, mass treatment with ivermectin is
contraindicated because of the risk of severe side effects associated
with death of Loa loa microfilariae [4]. These circumstances argue
strongly for the development of vaccines to complement drug
treatment strategies.
Filarial nematodes are tissue-dwelling parasites that can be
killed by exposure to Th2-mediated effector mechanisms, with
eosinophils and antibody particularly critical for protection against
re-infection [5]. However, these parasites establish chronic
infections in a large number of species, including ,150 million
humans in whom immunopathological reactions cause a spectrum
of clinical diseases. The persistence of filarial parasites has been
shown to be enabled, in part, by excretory/secretory (ES) products
[6–10]. As a consequence, the efficacy of a vaccine against filarial
infections is likely to depend on how well it disrupts parasite
immune evasion mechanisms. Given that the maintenance and
transmission of filarial infections requires very few adult parasites
[11] and that our previous work suggests that they are able to
increase their fecundity in response to host immune attack [12],
any intervention strategy should be assessed by its ability to
suppress the transmissible stages, the microfilariae. Not only is this
critical to reducing disease transmission, but in onchocerciasis
microfilariae are the main cause of pathology.
The rodent filarial nematode, Litomosoides sigmodontis, has been
used to elucidate many of the regulatory pathways that allow
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parasite establishment and is ideally suited for assessing vaccina-
tion success against filarial nematodes as the parasites can develop
patent infections in BALB/c mice [5,13]. The infective larvae are
inoculated subcutaneously, and over 4–6 days migrate to the
pleural cavity, where they mature to adulthood, mate and produce
microfilariae that enter the bloodstream by 60 days post-infection.
Consequently, protective immunity against all stages of the
parasite’s lifecycle can be assessed. We tested the vaccine potential
of two L. sigmodontis immunomodulatory ES products by expres-
sion of these proteins in DNA vaccine constructs designed to
improve antigen presentation and enhance Th2 immune responses
[14,15].
While there have been previous attempts to immunise rodents
against filarial nematodes using DNA vaccines [16–18], this is the
first study to do so that specifically targets parasite-driven immune
modulation and uses a filarial parasite that produces patent
infections in laboratory mice, thus allowing manipulation and
deeper examination of host immunity through methodology
developed in inbred mice.
Materials and Methods
Ethics statement
All procedures involving animals were approved by the Univer-
sity of Edinburgh ethical review committee, and performed under
license from the UK Home Office in accordance with the Animals
(Scientific Procedures) Act 1986.
Mice and parasites
All immunisations and infections were performed with female
BALB/c mice, starting at ages of 6–7 weeks. Mice were housed
in individually ventilated cages and infected subcutaneously
with 30 or 40 L. sigmodontis infective larvae (iL3). Two experi-
ment endpoints were chosen based on the life cycle of L.
sigmodontis, D10 post-inoculation (p. i. ) when most larvae will
have reached the L4 stage; and, at D60 p. i. after the onset of the
patent phase.
Cloning and mutation of LsALT and LsCPI
All cloning was carried out following the recommendations of
the pcDNA 3.1 Directional TOPO Expression Kit (Invitrogen).
LsALT (DQ451171.1) and LsCPI (AF229173.1) were amplified
from a cDNA preparation of L. sigmodontis iL3 with the primers
detailed in Table S2. The desired mutation of asn66 to lys66 in
LsCPI was generated with the QuikChange Site Directed
Mutagenesis Kit (Stratagene) using primers detailed in Table S2.
Fusion constructs containing single-chain anti-DEC205 antibody
(DEC) upstream of our target antigen were produced from ready-
made constructs kindly provided by Dr. Ralph Steinman [19].
Briefly, PCR products of genes of interest were digested with NotI
and XbaI (Neb laboratory, UK), then ligated into an NotI and
XbaI-digested anti-mouse dec-205 single chain antibody -
ovalbumin construct (DEC-OVA) or antibody control Ig-OVA
to replace the fragment of OVA gene, respectively. All plasmids
were sequenced to confirm identity.
Protein expression for ELISA
LsALT and LsCPI were cloned into pET21b and pET29c
respectively. Both plasmids were made with PCR products derived
from primers spanning the full CDS minus the stop codon and
with flanking restriction enzyme recognition sites. The recombi-
nant CPI and ALT containing a T7 tag at the N terminus and His
tag at the C terminus were produced in the E. coli BL21(DE3)
strain (Novagen UK) and purified on His- binding resin columns
using automated AKTAprime (Amersham Pharmacia).
Immunisations and challenge
Plasmids were injected in the tibialis anterior muscle of the left
leg with a 27G needle, immediately followed by electroporation
with an ECM 830 generator+Tweezertrodes (BTX Harvard
Apparatus) using as settings 8 pulses, 200 V/cm, 40 ms duration,
460 ms interval [20]. Each mouse was immunised twice separated
by 2 weeks interval with 40 mg of DNA total made up by equal
quantities of each plasmid species, delivered in 50 ml PBS. As a
consequence, the quantity of each individual plasmid was reduced
as the number of different plasmids incorporated into the
inoculums increased. However, the quantity of each one remained
in excess of the minimal efficient dose [21]. In vivo expression of the
gene of interest was determined by the detection of mRNA with
specific primers 4 weeks after immunisation (Figure S1 and Table
S3). Mice were challenged 4–6 weeks after the last immunisation.
Immunological read-outs
Blood was collected from individual mice after the first
immunisation, then every other week to measure the increase in
antibody titres. At experiment end point cells were recovered from
thoracic lymph nodes for antigen recall assays of specific cytokine
production and proliferation. Pleural lavage fluid was also
collected for cytokine and cellular infiltrate measurement.
Cytokines IL-4, IL-5, IL-10, IFN-c and IL-13, and total IgE
levels were measured by sandwich ELISA, and specific anti-L.
sigmodontis IgG1 and IgG2a responses were measured by indirect
ELISA against whole soluble extract coated at 10 mg/ml, and anti-
LsALT or anti-LsCPI antibodies against the respective native
recombinant proteins coated at 5 mg/ml using the antibody pairs
described elsewhere [22] and detected with TMB-H2O2+(KPL) at
450 nm. Titres were assessed by two fold serial dilution of the
serum, and determined as the highest dilution factor for which O.
D. values exceeded 3 standard deviations above control wells from
the same plate. All ELISAs were repeated at least once. The 1/800
O. D. was used in some analyses.
Author Summary
Filarial infections are endemic in more that 80 countries,
affecting over 120 million people and putting 1 billion
more at risk. Antifilarial drugs must be administered
regularly to infected people to control the disease, but
they are contraindicated in under 6 year-olds and in
pregnant women. Further, reports of drug resistance are
now accumulating. A vaccine would therefore greatly help
fight these diseases. Live attenuated L3 filariae larvae can
evoke a protective immunity but their production is
impractical and use in humans unacceptable while the
efficacy of sub-unit vaccines has been poor. Filariae secrete
proteins capable of suppressing their host’s immune
response, and have the potential to interfere with
immunisation. We therefore decided to vaccinate hosts
against secreted parasite products that modulate host
immune responses rather than against structural compo-
nents of the worms, and to boost the host’s immune
system by directly enhancing the uptake of parasite
material by antigen presenting cells. This strategy gener-
ated substantial protection against both adult and
offspring of a filarial parasite in mice. This provides a
strong proof of principle for the anti-immunomodulatory
approach we have developed.
Anti-Immunomodulatory Filarial DNA Vaccine
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Parasitological read-outs
Parasite survival was determined at experiment endpoint. Adult
filariae were isolated from the pleural cavity lavage fluid in10 ml
cold PBS, fixed in hot 70% ethanol and counted. Protection was
calculated as (mean burden in primary infected animals - mean
burden of vaccinated animals)/mean burden in primary infected
animals. Microfilariae were counted in 30 ml of blood after fixation
in 570 ml of BD FACS lysing solution (BD Biosciences) under an
inverted microscope.
Data analysis
Generalised linear models (GLM) were used to compare the
effects of different vaccine formulations on parasitological and
immune parameters as they allow more flexibility in specifying the
distribution of response variables and better model fitting through
Maximum Likelihood estimation. Parasite and cell counts were
modelled assuming poisson or negative binomial error distribu-
tions; antibody levels were log-transformed. Homoscedasticity and
normality of the residuals were assessed with the Fligner-Killeen
test of homogeneity of variances and the Shapiro-Wilk normality
test, respectively. The non-parametric Kruskal-Wallis rank sum
test followed by pairwise comparison with the Wilcoxon rank sum
test with Bonferroni correction for multiple comparisons were
applied to data that didn’t conform to a standard distribution.
Average parasite counts per group were used to calculate pairwise
measures of protection. A principal component analysis (PCA) was
performed to identify major trends across the large number of
immunological measures performed. Briefly, data were scaled to
null mean and unit standard deviation, and the broken-stick
criterion was then used to select the principle components having
the best explanatory power [23]. The biological interpretation of
the resulting PC was then based on the relative contribution of
each immune factor to it, e.g. a preponderance of Th2-associated
factors or of pro-inflammatory factors. Individuals’ predicted
values from the PCA were then used as explanatory variables in a
GLM to assess which components were best correlated with
parasite killing. Statistical analyses are reported in figures and
legends only when significant effects of vaccine formulations were
found. All analyses and graphs were performed in R 2.15 [24].
Results
Suppression of ALT-driven immune modulation
enhances immunisation
LsALT is the most abundant transcript produced by the
infective larvae of filarial nematodes [25,26], and is suspected of
modulating the host Th2 immune responses [9]. ALT’s potential
as a vaccine has been tested by several laboratories using different
filarial and host species and has shown variable success in inducing
immunity [17,25,27–31]. As a starting point for this study the
immunisation efficacy of plasmids containing L. sigmodontis antigens
was enhanced by electroporation into skeletal muscle [32].
However, our attempts using plasmids expressing LsALT (ALT)
to immunise mice against L. sigmodontis failed to induce Th2
responses. We thus wanted to improve immunisation efficacy
against LsALT by specifically enhancing Th2 responses with IL-4,
and by enhancing dendritic cell recruitment and activation. Levels
of IgG2a, IgG1and IgE were measured to determine the relative
balance between Th1 and Th2 responses while IL5 production
and eosinophil numbers where used as measures of vaccine-
induced immunity against the filariae [33,34].
BALB/c mice immunised with ALT and challenged with
infective L. sigmodontis larvae, failed to generate LsALT-specific
IgG responses or local eosinophil recruitment ten days after
challenge. Although not reaching significance, the co-administra-
tion of plasmids encoding IL-4 (pIL4) increased LsALT-specific
IgG1 but not IgG2a levels, while antigen presenting cell activators
MIP-1a (pMIP) and Flt3L (pFlt3L) [35] marginally increased both
IgG1 and IgG2a (Figure 1A–B).
Coinjecting ALT with pMIP+pFlt3L significantly increased the
production of total IgE production compared to ALT alone
(Figure 1C). There was an indication that eosinophil recruitment
to the site of infection was also increased by the addition of pIL-4
and pMIP+pFlt3L compared to ALT alone (Figure 1D). The
vaccine containing ALT alone resulted in non-significantly higher
parasite survival than in pEmpty controls (Figure 1E), while the
addition of pIL4 or pMIP+pFLt3L seemed to counter this facilita-
tion. Overall, no protection was detected at day 10 post-challenge.
These data showed that ALT could generate specific antibodies,
but that it was poorly immunogenic, and possibly immunomod-
ulatory. Previous data have suggested that the variable acidic
domain of Brugia malayi ALT-2 confers the protein its immune
modulatory properties [9]. We thus decided to generate a mutated
LsALT lacking the acidic domain (ALTm) in the hope that this
would enhance LsALT-specific immune responses to the remain-
ing epitopes. Immunising with ALTm resulted in a significant
increase in LsALT-specific IgG1 production above naı¨ve controls
and a marginal increase above the native form ALT (Figure 2A),
consistent with the hypothesis that the deletion of the acidic
domain would overcome LsALT-driven immunosuppression. The
ALTm vaccine induced a strong increase in LsALT-specific IgG2a
concentrations above naı¨ve controls (Figure 2B), but no further
increase above the native form ALT. Although total IgE
production and eosinophil recruitment were higher in the ALTm
group than in the ALT group, this was not statistically significant
(Figure 2C–D). Despite relatively high antibody production in
several repeats of this experiment, significant protection against a
challenge infection was never achieved (Figure 2E).
In an attempt to enhance the protective potential of ALTm, a
plasmid was constructed to encode a fusion protein comprising
ALTm and an anti-DEC205 single chain Fv antibody (decALTm).
The expressed fusion protein directly binds dendritic cells through
the DEC205 surface receptor [19]. A second plasmid encoding a
fusion protein comprising an antibody with irrelevant specificity
and ALTm (isoALTm) was constructed for use as a control. For
these experiments we chose to include pIL-4, pMIP and pFlt3L in
all vaccine formulations to maximise their protective potential.
Immunising with decALTm resulted in increased LsALT-specific
IgG1 and IgG2a concentrations in 2 out of 5 mice, but did not
increase total IgE or eosinophilia above the non-DC-targeted
form, ALTm (Figure 3A–C). Despite demonstrable enhancement
of IgG1 antibody levels by both ALTm and decALTm compared
to empty vector, no statistically significant reduction in parasite
numbers was detected at day 60 post-challenge (Figure 3E). This
suggests that immunising against LsALT alone was not sufficient
to evoke protective immunity.
Suppression of CPI-2-driven immune modulation
enhances immunisation
Because removal of immune modulatory sequences from
LsALT had a significant impact on its ability to induce an
immune response, we decided to apply a similar approach to
another immune modulatory filarial protein. Filarial cystatins are
potent downregulators of inflammation [36] and antigen process-
ing by host cells, as shown for CPI-2 from B. malayi which inhibits
asparaginyl endopeptidase activity [37]. We isolated the L.
sigmodontis homologue, LsCPI, and cloned it into the same
Anti-Immunomodulatory Filarial DNA Vaccine
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Figure 1. Coinjection of plasmids encoding IL-4 and MIP-
1a+FLT3L marginally improves immunisation with LsALT-
expressing plasmids. Mice were immunised with DNA plasmids
expressing parasite LsALT (ALT) and murine IL-4 (pIL4) or MIP-1a (pMIP)
and Flt3L (pFlt3L). Empty expression plasmid (pEmpty) was injected as a
control for DNA-induced inflammation to equalise DNA quantities
between groups. All groups were subsequently challenged with live
infective L. sigmodontis larvae subcutaneously and infection was
allowed to progress for 10 days. (A–B), LsALT-specific IgG1 and IgG2a,
respectively and (C), concentrations of total IgE in the serum were
increased by the coadministration of pMIP and pFlt3L compared to ALT
alone (b, P= 0.03). (D), Eosinophil recruitment to the site of infection,
the pleural cavity. Cell enumerations were performed on pleural lavage
fluid. (E), Parasite survival represented as the proportion of worms
found in the pleural cavity of infected mice relative to the infective
dose. Points represent individual mice at D10 p.i. (N = 5–6 mice per
group).
doi:10.1371/journal.pntd.0001968.g001
Figure 2. DNA immunisation with inactivated LsALTm enhanc-
es Ls-ALT-specific humoral responses. Mice were immunised with
DNA plasmids expressing the native sequence of LsALT (ALT), the acidic
domain-deleted form (ALTm), or nothing (empty expression plasmid
pEmpty). All groups except naı¨ve mice were challenged with live
infective L. sigmodontis larvae and the infection was allowed to progress
for 10 days. (A–B), LsALT-specific IgG1 and IgG2a concentrations in
serum (A: c vs. [a, bc, b], P = 0.002, 0.1, 0.05; B: a vs. b, P#0.02). (C), Total
serum IgE levels. ELISAs were performed with the complete recombi-
nant LsALT. (D), Total eosinophil numbers in the pleural cavity. (E),
Parasite survival represented as the proportion of worms found in the
pleural cavity of infected mice relative to the infective dose (except
naive mice). Points represent individual mice (N = 5 mice per group).
doi:10.1371/journal.pntd.0001968.g002
Anti-Immunomodulatory Filarial DNA Vaccine
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pcDNA3.1 vector as LsALT, either in its native sequence (CPI) or
with a mutation that disrupts its AEP inhibitory activity (CPIm).
To verify our previous findings with immune enhancing
plasmids the native and modified constructs of LsCPI were
administered with or without pIL4+pFlt3L+pMIP (indicated as
+adj in figure 4). LsCPI-specific IgG1 production was significantly
enhanced by the co-administration of pIL4+pFlt3L+pMIP
(Figure 4A). The combination of the mutation of CPI and
pIL4+pFlt3L+pMIP significantly enhanced the production of IgE
compared to all the other groups (Figure 4B). However, no
protection from challenge infection was achieved by the vaccine
regimens above (Figure 4C). We therefore followed the DC-
targeting strategy used with ALT: CPI and CPIm were fused with
a scFv-DEC205 sequence (decCPI and decCPIm, or isoCPI for
scFv isotype control). All groups received pIL4+pFlt3L+pMIP, as
this had also improved immunisation against LsALT (Figure 3). In
this experiment, both the mutation of CPI and the targeting of
dendritic cells enhanced immune responses to LsCPI. The
resulting CPIm and decCPIm constructs induced strong increases
in LsCPI-specific IgG1 compared to isoOVA-, CPI- and CPIm-
immunised animals (Figure 5A) and in IgG2a compared to CPI
(Figure S2A) as well as total IgE (Figure 5B). Nonetheless, there
was no significant protection as neither adult worm recoveries
(Figure 5C) nor microfilariae densities (Figure 5D) differed
statistically between control mice and mice immunised with CPIm
or decCPIm. However, the mutation of CPI showed a trend
towards reduced microfilariae in the peripheral circulation
(Figure 5D).
Protective immunity achieved by dual modified antigen
vaccine
On their own neither ALT or CPI induced a substantial
protective effect. However, recombinant vaccines can work more
effectively in combination [16,27,38–40] and indeed in a cattle
model of onchocerciasis both ALT and CPI were part of a cocktail
of recombinant proteins that generated protection against natural
challenge [41]. We thus chose to use a combination of both
parasite antigens along with the full complement of ‘adjuvant’
plasmids in an effort to increase the level of protection. Significant
protection was achieved when mice were immunised with dual
modified parasite antigens and the full combination of cytokine-
expressing plasmids (Figure 6). Adult parasite numbers were
reduced by 71% in the mice that received the full modified vaccine
relative to those that received unmodified antigens ALT+CPI, by
65% compared to those that received ALTm+CPIm+adjuvants
and by 68% compared to those that received only empty plasmids
(Figure 6A). Average microfilaraemia in both the full vaccine and
the ALTm+CPIm groups was reduced by over 85% compared to
both the ALT+CPI group and empty plasmid controls (Figure 6B).
The lack of protection in the ALT+CPI group suggests that
combining vaccine targets is not sufficient on its own. Further, the
benefit of targeting the antigens to dendritic cells via DEC205 was
to induce more rapid killing of adult parasites.
The importance of the ‘adjuvants’ was confirmed in a separate
experiment. Significant protection was achieved by D60 post-
challenge in the groups that received the dual vaccine dec-
ALTm+decCPIm, reaching an average 82% reduction of adult
Figure 3. Dendritic-cell targeted ALTm enhances humoral and
cellular responses against LsALT. The sequence encoding ALTm
was fused to the sequence for a single-chain antibody targeting
DEC205 (decALTm) or to a control antibody sequence which was
derived from an antibody of the same isotype that does not bind to
DCs). All vaccinated mice were also injected with pIL-4, pMIP and
pFlt3L. All groups except naı¨ve mice were challenged with live infective
L. sigmodontis larvae. The data shown are representative of results
obtained at D10 and at D60 p.i. (A) Serum LsALT-specific IgG1 levels
were significantly increased in the ALTm and decALTm groups relative
to the control plasmids (b vs. [a, ab], P#0.05, 0.8). (B) LsALT-specific
IgG2a concentrations in serum were highly variable. ELISAs were
performed with the wild-type recombinant LsALT. (C) Targeting ALTm
to dendritic cells did not increase total total serum IgE or (D), eosinophil
recruitment to the site of infection but IgE was significantly higher than
in naı¨ve controls (C, P= 0.02). Cytokines and cell enumerations were
performed on pleural lavage fluid. (E), Parasite survival represented as
the proportion of worms found in the pleural cavity of infected mice
relative to the infective dose (except naive mice). pEmpty, non-coding
plasmid control; ALTm, plasmid encoding the acidic domain-deleted
sequence of LsALT; isoALTm, plasmid encoding a non-specific scFv
control-ALTm construct; decALTm, plasmid encoding the anti-DEC205
scFv-ALTm construct. Points represent individual mice (N = 5 mice per
group).
doi:10.1371/journal.pntd.0001968.g003
Anti-Immunomodulatory Filarial DNA Vaccine
PLOS Neglected Tropical Diseases | www.plosntds.org 5 December 2012 | Volume 6 | Issue 12 | e1968
parasite burden relative to non-vaccinated animals (Figure 6C),
and a 90% reduction of circulating microfilariae (Figure 6D). The
dramatic effect on microfilariae numbers without full removal of
the adult population suggested that at least some of the vaccine
impact was occurring late in infection and was specifically
targeting larval stages or worm fecundity.
To determine the relative contribution of the ‘adjuvant’
plasmids to protection, mice were immunised with decALTm+-
decCPIm with either pIL4, pMIP+pFlt3L, or both as in the full
vaccine. While the reduction in adult worm counts by the full
vaccine formulation reached 57%, the formulation with pIL4
alone showed no protective effect relative to pEmpty controls, and
the formulation containing MIP+pFlt3L achieved 64% protection
(Figure 6E). Effects of these formulations on the microfilariae were
interesting (Figure 6F): in mice that became positive for
microfilariae, vaccination with pMIP+pFlt3L reduced microfila-
raemia by 90%; with pIL4+pMIP+pFlt3L, microfilariae counts
were reduced 70%; however pIL4 caused a 1.56 increase in
average microfilariae numbers in patent mice, which is consistent
with our findings that IL-4 is associated with eosinophil-induced
increase in worm fecundity in vaccinated animals [12,42]. Despite
considerable variability in worm recoveries we have always found
(5 experimental repeats) that the comparison between pEmpty and
the full vaccine has exceeded 65% reduction in microfilaraemia.
These data suggest that targeting immune modulatory proteins
had protective effects against multiple parasite stages with substan-
tial IL4-independent disruption of microfilariae production and
gradual killing of adults, consistent with the finding that early dis-
ruption of Treg function during the onset of L. sigmodontis infection
is sufficient to enhance microfilarial killing 60 days later [43].
Figure 4. Removal of asparaginyl endopeptidase inhibition by
LsCPI increases its immunogenicity. Mice were immunised against
LsCPI with plasmids encoding either the native protein (CPI) or a
plasmid expressing its mutated form (CPIm), in combination with
pIL4+pFlt3L+pMIP or alone. All mice other than naı¨ve were challenged
with live infective L. sigmodontis larvae. (A), LsCPI-specific IgG1 (b vs. [a,
ab], P = 0.02, 0.3), and (B), total serum IgE concentrations (a, P#0.001).
ELISAs were performed with recombinant LsCPI. (C), Parasite survival
60d after infection. pEmpty, non-coding plasmid control; CPI, pcDNA
3.1 plasmid with an insert encoding LsCPI; CPIm, mutated form of LsCPI;
adj = pIL4+pFlt3L+pMIP. Points represent individual mice at D60 p.i.
(N = 5 mice per group).
doi:10.1371/journal.pntd.0001968.g004
Figure 5. Enhancing type 2 immunity against LsCPI by
targeting DCs. Mice were immunised with plasmids containing the
CPI, decCPI, CPIm or decCPIm construct. (A), LsCPI-specific IgG1
concentrations (b vs. a, P#361025), (B), total IgE serum concentrations
(a, P#0.05), and (C–D) adult parasite survival and microfilariae
peripheral blood densities. All groups except naı¨ve received
pIL4+pFlt3L+pMIP. isoOVA, control plasmid expressing OVA fused to
an isotype control for sc-Fv-DEC205; CPI, pcDNA 3.1 plasmid with an
insert encoding LsCPI; CPIm, mutated form of LsCPI. Points represent
individual mice at D60 p.i. (N = 5 mice per group).
doi:10.1371/journal.pntd.0001968.g005
Anti-Immunomodulatory Filarial DNA Vaccine
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Immune determinants of protective immunity
Many of the readouts assessed for this study did not reach
statistical significance, perhaps due to high variability in both
immune parameters and parasite numbers. We took statistical
advantage of the substantial variation in both immune and
parasitological read-outs to analyse the most prominent immune
correlates of protection observed in Figure 6C. For example,
pleural recruitment of eosinophils and parasite-specific IgG1
production were increased in the dual-vaccinated group (Figure
S2B–C) although no significant effect on total IgE production was
detected (Figure S2D). In total, thirty-one variables for each mouse
(Table S1) were measured. To facilitate their analysis, we reduced
them to principal components (PC) that summarise major patterns
in the immune response. Three PC tested as significant and
interpretable that captured 50% of the variation present in the full
dataset (Table 1, Figure S3). Subsequent components were
rejected for lack of explanatory power. The first component
(PC1) included mainly lymph-node cell production of Th2
cytokines IL-5 and IL-13. PC2 included whole worm-specific
IgG1, pleural IL-5, and pleural eosinophils, neutrophils, macro-
phages and less prominently, pleural lymphocytes. PC3 included
mainly LsALT- and LsCPI2-specific IgG1, unstimulated IL-4
production by lymph node cells in vitro, anti-CD3 induced
production of IFN-c and pleural lymphocyte numbers (see Table
S1 for individual rotation values). The explanatory power of the
resulting components for parasite survival was assessed by GLM.
Parasite numbers were affected by only the second principal
component PC2, revealing a strong negative correlation between
PC2 and parasite survival (Figure 7). An analysis of variance
confirmed that the decALTm+decCPIm vaccine formulation
drove most of the variation in PC2 (Figure 7).
Figure 6. Dual modified antigens in combination with cytokine-expressing plasmids generate protective immunity. Mice were
immunised with decALTm, decCPIm, or both in addition to the adjuvant combinations pIL4+pFlt3L+pMIP, pIL4 alone or pFlt3L+pMIP. (A–B),
Comparison of dual unmodified antigens and dual modified antigen formulations. (C–D), comparison of single modified vs. dual modified vaccine
protective capacity. (E–F), comparison of Th2- and antigen presenting cell-promoting plasmids. (A, C, E), Proportion of adult parasites present in the
pleural cavity of mice after 60 days of infection relative to infection dose (A: a, P,4610213; C: c vs. [b, ab, a], P = 0.002, 461025, 361027). (B, D, F),
number of microfilariae present in 30 ml of peripheral blood circulation (B: c vs. [b, a], P = 0.004, 8610214; F: b vs. a, Pd,0.04). pEmpty, non-coding
plasmid control; decALTm, plasmid encoding the anti-DEC205 scFv-ALTm construct, decCPIm, plasmid encoding the anti-DEC205 scFv-CPIm
construct, pIL4 pMIP and pFlt3L, plasmids expressing mouse IL-4, MIP-1a and Flt3L respectively. Points represent individual mice at D60 p.i. (A–D,
N = 4–5 mice per group; E–F N = 9–10 mice per group).
doi:10.1371/journal.pntd.0001968.g006
Table 1. Importance of principal components of
immunological responses.
PC1 PC2 PC3
Standard deviation 2.657 2.197 1.902
Proportion of Variance 0.228 0.156 0.117
Cumulative Proportion 0.228 0.384 0.500
The first four components obtained from a PCA analysis of 31 immunological
factors measured in vaccinated and challenged mice captured 56.5% of the
total variation present in the full dataset. For the detailed contributions of the
immunological factors to each principal component, please see Table S1.
doi:10.1371/journal.pntd.0001968.t001
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Because IgE was weakly represented in those PCs while IgG1
was strongly represented in PC2, we wanted to determine the
relative contribution of IgE, IgG1 and IgG2a concentrations to
parasite killing. This confirmed that only IgG1 had a significant
effect on parasite numbers (P= 0.015). Likewise, the analysis of
respective roles for pleural cell types in protection revealed that
parasite killing was significantly affected by pleural lymphocytes
and neutrophils (P= 0.002 and P= 0.03 respectively), but only
marginally by eosinophil numbers (P= 0.07) despite a significant
negative correlation between eosinophil and parasite numbers
(r =20.5, P= 0.02). Taken together, these data are strongly
suggestive of IgG1 and pleural leukocytes as being the main
effectors in the decALTm+decCPIm vaccine-induced parasite
killing.
Discussion
Like many parasitic helminths, filarial nematodes establish long-
lasting infections that are facilitated by immunomodulatory
products secreted by the parasite [7]. Host-driven immune
down-regulation can contribute to parasite survival [13], while
in other patients, anti-filarial responses to adult and juvenile
parasites are associated with immunopathology. Indeed, since
immunity to helminths is mainly mediated by Th2-type responses,
the risk of a vaccine generating excessive eosinophilia, IgE-
mediated mast cell degranulation and related pathologies must be
considered carefully [44]. Finally, we have previously demonstrat-
ed that filarial nematodes are able to adapt their developmental
schedule to the hosts’s eosinophilic response, thereby shortening
their time to transmission [12]. We thus inferred that a successful
vaccine against filarial infections would need to: (a) evoke a Th2
response, possibly through a path different from that driven by
natural challenge; (b) target the parasite molecules that sup-
press protective immunity; (c), avoid inducing immune hyper-
responsiveness. This suggested that the best vaccine candidates
would be found among excreted/secreted molecules rather than
structural components.
We selected parasite antigens based on their abundance in gene
expression profiles [25,26], potential to induce protective immu-
nity [31,45], and on their role in immune modulation as supported
by in vitro studies [8,9], and decided to take advantage of
the flexibility and ease of production of DNA vaccination.
Administering plasmids encoding the native sequences of LsALT
and LsCPI failed to generate strong specific immune responses in
mice, perhaps because of the immunomodulatory properties of
these proteins when directly expressed in eukaryotic cells. This
differs from other DNA vaccination studies in which ALT from
the human parasite B. malayi induced a good response in rodents
following challenge [17,27,28]. It may be that the immune
modulatory properties of ALT are host-specific and are more
readily manifested in the permissive host-parasite combination
used in our study. Indeed our finding that when LsALT and
LsCPI were genetically modified to remove immune modulatory
residues, specific antibody responses increased, provides in vivo
support to the in vitro evidence that these domains are immuno-
suppressive [8,9]. It further indicates that the immunosuppressive
function of these proteins can be successfully removed in vivo,
thereby allowing vaccines that contain them to generate significant
protection against multiple stages of the parasite.
Simultaneously with the plasmids expressing parasite antigens,
we administered plasmids expressing host cytokines IL-4 to
enhance Th2 responses required for the elimination of filarial
infections [5], as well as MIP-1a and Flt3L to enhance activation
and recruitment of dendritic cells [19,46,47]. In addition, a
sequence encoding a single-chain Fv antibody directed against the
dendritic cell surface marker DEC-205 [19] was added to the
parasite sequence in order to maximise the uptake of antigen by
the DCs recruited by MIP-1a, Flt3L and the injections. We
hypothesise that it is the combination of these steps that lead to
successful protection against infection. Further, our results
demonstrate the feasibility of combining different adjuvant systems
in a single vaccine to increase its efficacy. However, our
parasitological data display substantial variability, especially in
the rate of adult worm killing. This variability is inherent to the
study system, and is consistent with that observed in natural filarial
infections [41,48–50].
A recurring problem with DNA immunisation has been the lack
of protective immunity despite the ability to generate specific
immune responses [1]. The gold standard of vaccination against
filarial nematodes is immunisation with irradiated larvae, and
requires the presence of functional eosinophils and antibody
[51,52]. A multivariate analysis of the immune factors that lead to
protection in our present study revealed a negative correlation
between whole parasite-specific IgG1 (measured in the blood) and
Figure 7. Protective immunity is mediated by IgG1 and pleural leukocyte recruitment. A principal component analysis was performed on
31 immunological measures from the mice in Figure 6C–D (see Table S1 and Figure S3 for PC selection) to identify immune responses associated with
the killing of adult worms. The second component was most strongly associated with parasite-specific IgG1 and pleural leukocyte recruitment, and
was the only component negatively correlated with parasite survival (r =20.72, P,0.0001). pEmpty, non-coding plasmid control; decALTm, plasmid
encoding the anti-DEC205 scFv-ALTm construct, decCPIm, plasmid encoding the anti-DEC205 scFv-CPIm construct, pIL4 pMIP and pFlt3L, plasmids
expressing mouse IL-4, MIP-1a and Flt3L respectively. Points represent individual mice at D60 p.i. (N = 5 mice per group).
doi:10.1371/journal.pntd.0001968.g007
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the numbers of leukocytes at the site of infection, implying that
immune effectors were correctly potentiated during the immunisa-
tion phase. Intriguingly, serum concentrations of IgE did not
correlate with parasite numbers, despite being enhanced by the
most protective vaccine regimens, and mediating protection in
another rodent model of vaccine-mediated L3 killing [52]. A further
consequence of this finding is that IgG1 and antigen-specific T cell
responses may be sufficient to assess immunisation efficacy and the
generation of protective immunity, but that IgE may not be an
accurate marker for protection in mice, which may be due to the
lack of Fc epsilon receptors on murine eosinophils [53]. The more
prominent association between neutrophilia and protection is in
accordance with other studies showing their role in secondary
immunity to Strongyloides stercoralis in mice [54]. Further, our data
suggest that in addition to the importance of targeting the parasite
directly, the choice of adjuvants is crucial to generating immune
responses that are protective. The coinjection of IL-4, MIP-1a and
Flt3L lead to substantial reductions in parasite numbers, which was
maintained or even improved when only MIP-1a and Flt3L were
administered. Further refinements of this vaccine formulation are
underway, but it currently appears that both DEC205 and MIP-
1a+Flt3L are needed but the IL-4 may be dispensable.
In conclusion, strategic use of DNA vaccine technology has
allowed us to test a large number of parameters and combinations
of immune modulators that would not have been logistically
possible if we needed to produce all the individual recombinant
proteins in active form. This study provides a proof-of-principle
that targeting parasite products that suppress the immune
responses of their hosts while enhancing antigen presentation
can lead to significant protection. Anti-evasion immunisation is
garnering an increasing amount of attention in a wide range of
pathogenic systems [55–58]. Our study shows that it is crucial and
feasible to ablate the immunomodulatory function of such
candidates for them to generate protective immune responses
and we expect that this strategy may be applied to a wide range of
diseases. Whether or not successful immunisation against filarial
and other pathogens includes DNA vaccination, the work
described here provides an approach to define the antigens and
modulators most likely to generate very high levels of protection
against all stages of infection, along with the ability to define the
best correlates of protection.
Supporting Information
Figure S1 mRNA expression from plasmids injected to
the muscle. To verify that plasmids were successfully transcribed
in the muscle, RT-PCR and cDNA amplification with specific
primers were performed on mice 28 days after the second
immunisation. Samples from two experiments and 3 mice for each
group are shown. (A and B) ALTm and OVA mRNA expression
respectively. Lanes 1–3: mice immunised with decALTm; lanes 4–
6: mice immunised with isoOVA; lanes 7–9: Naive mice (C and D)
CPI or CPIm, and OVA mRNA expression, respectively. Lanes
1–3: mice immunised with decCPI; lanes 4–6: mice immunised
with decCPIm; lanes 7–9: mice immunised with isoOVA; lanes
10–12: Naive mice. See Table S3 for expression in other organs.
(TIFF)
Figure S2 Increased antibody production against L.
sigmodontis soluble antigen and CPI when DCs are
targeted. (A) LsCPI-specific IgG2a concentrations in the serum
of mice were immunised with plasmids encoding either the native
protein (CPI) or a plasmid expressing its mutated form (CPIm), in
combination with pIL4+pFlt3L+pMIP or alone. All mice other
than naı¨ve were challenged with live infective L. sigmodontis larvae
(GLM, PdecCPIm, [CPI, decCPI, CPIm, isoOVA] = 0.002, 0.2, 0.6, 0,001).
(B) Whole parasite-specific IgG1 titres, (C), numbers of eosinophils
in the pleural cavity, and (D) total IgE concentrations in mice
immunised with decCPIm and decCPIm in addition to the
adjuvant cocktail pIL4+pFlt3L+pMIP 60 days post-challenge (see
Figure 7). pEmpty, non-coding plasmid control; decALTm,
plasmid encoding the anti-DEC205 scFv-ALTm construct,
decCPIm, plasmid encoding the anti-DEC205 scFv-CPIm con-
struct. Points represent individual mice (N = 5 per group).
(TIFF)
Figure S3 Selection of interpretable principal compo-
nents. The broken-stick criterion was used to select the most
significant components. PC1 through 3 captured 50% of the
variation present in the full dataset, and were then used as
explanatory factors in a GLM with parasite numbers as the
response variable. Detailed methods are presented in the data
analysis section of Materials and Methods.
(TIFF)
Table S1 Rotation of significant principal components.
Rotations of the first four principal components obtained from a
PCA analysis of 31 immunological factors measured in vaccinated
and challenged mice. The major contributing factors (underlined)
were used to identify the immunological function most closely
conveyed by each PC.
(DOC)
Table S2 Primers used for cloning Litomosoides sigmo-
dontis and mouse genes.
(DOC)
Table S3 Tissue distribution of ALT, ALTm, OVA, CPI
and CPIm vaccines in mice by RT-PCR. To assess where
plasmids that were injected intramuscularly were expressed, RT-
PCR and cDNA amplification with specific primers were
performed on muscle, spleen, lungs and liver of mice 28 days
after the second immunisation. Average abundance on a scale
from 1 to 3 was estimated on a 1% agarose gel after PCR from the
same mass of first strand cDNA, since quantitative PCR failed to
detect some of the samples. Samples from two experiments and 3
mice for each group are shown.
(DOC)
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